US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Phio Pharmaceuticals

1.09

-0.0300-2.68%

Post-market: 1.08-0.0132-1.21%19:47 EST

Volume:120.57K

Turnover:133.22K

Market Cap:11.73M

PE:-0.43

High:1.14

Open:1.14

Low:1.08

Close:1.12

52wk High:9.79

52wk Low:0.9657

Shares:10.76M

Float Shares:10.71M

Volume Ratio:0.27

T/O Rate:1.13%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-2.5229

EPS(LYR):-9.0798

ROE:-107.58%

ROA:-60.16%

PB:1.19

PE(LYR):-0.12

Loading ...

Overview Company News Filings

Phio Pharmaceuticals Completes Enrollment for PH-762 Trial

Phio Pharmaceuticals Completes Phase 1b Enrollment for PH-762 Skin Cancer Trial

Phio Pharmaceuticals CEO Robert J. Bitterman Reports Acquisition of Common Shares

BRIEF-Phio Pharmaceuticals Corp Files For Offering Of Up To 11.8 Million Common Shares By The Selling Stockholders - SEC Filing

Phio Pharmaceuticals files to sell 11.76M shares of common stock for holders

Phio Pharmaceuticals Corp Files for Offering of up to 11.8 Mln Common Shares by the Selling Stockholders - SEC Filing

THOMSON REUTERS

Phio Pharmaceuticals CEO Robert J. Bitterman Acquires Common Shares

Phio Pharmaceuticals to Present INTASYL siRNA Technology at Advanced Therapies USA Congress

Phio Pharma Q3 EPS $(0.44) Misses $(0.40) Estimate

Phio Pharmaceuticals Reports Positive PH-762 Skin Cancer Trial Results and Extends Cash Runway Into 2027

Phio Pharmaceuticals Unveils Phase 1b Clinical Results for INTASYL PH-762 in Skin Cancer Trial

Phio Pharmaceuticals Exercises Warrants for $13.4 Million

Phio Pharmaceuticals Shares Rise After Positive Trial Results for PH-762

Why Is Phio Pharmaceuticals Stock Up 75% Today?

Phio Pharmaceuticals Corp - Safety Committee Issues Favorable Review at Maximum Dose of Intasyl Ph-762- SEC Filing

THOMSON REUTERS

Phio Pharmaceuticals Appoints New Lead Independent Director

Phio Pharmaceuticals Appoints David Deming as Lead Independent Director

Phio Pharmaceuticals to Present INTASYL Technology Update at Renmark Financial Virtual Non-Deal Roadshow

Phio Pharmaceuticals Announces Positive Interim Results in Phase 1b Trial of INTASYL Compound PH-762 for Skin Cancer Treatment

Phio Pharmaceuticals Corp. Conducted Annual Stockholders Meeting

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/PHIO/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"PHIO","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PHIO\",,,,,undefined,":{"symbol":"PHIO","market":"US","secType":"STK","nameCN":"Phio Pharmaceuticals","latestPrice":1.09,"timestamp":1765832400000,"preClose":1.12,"halted":0,"volume":120567,"hourTrading":{"tag":"盘后","latestPrice":1.0768,"preClose":1.09,"latestTime":"19:47 EST","volume":4674,"amount":5055.3651,"timestamp":1765846051849},"delay":0,"floatShares":10714600,"shares":10764400,"eps":-2.522945,"marketStatus":"Closed","change":-0.03,"latestTime":"12-15 16:00:00 EST","open":1.14,"high":1.14,"low":1.075,"amount":133217.48041830002,"amplitude":0.058036,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.522945,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1765875600000},"marketStatusCode":5,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":1.12,"preHourTrading":{"tag":"盘前","latestPrice":1.1298,"preClose":1.12,"latestTime":"09:26 EST","volume":3387,"amount":3846.7774599,"timestamp":1765808771560},"postHourTrading":{"tag":"盘后","latestPrice":1.0768,"preClose":1.09,"latestTime":"19:47 EST","volume":4674,"amount":5055.3651,"timestamp":1765846051849},"volumeRatio":0.269873,"impliedVol":2.2612,"impliedVolPercentile":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PHIO\",,,,,undefined,":{"symbol":"PHIO","floatShares":10714600,"roa":"-60.16%","roe":"-107.58%","lyrEps":-9.079757,"volumeRatio":0.269873,"shares":10764400,"dividePrice":0,"high":1.14,"amplitude":0.058036,"preClose":1.12,"low":1.075,"week52Low":0.9657,"pbRate":"1.19","week52High":9.79,"institutionHeld":0,"latestPrice":1.09,"eps":-2.522945,"divideRate":0,"volume":120567,"delay":0,"ttmEps":-2.522945,"open":1.14,"prevYearClose":1.8,"prevWeekClose":1.12,"prevMonthClose":1.26,"prevQuarterClose":2.48,"fiveDayClose":1.13,"twentyDayClose":1.3,"sixtyDayClose":2.07},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/PHIO\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-11-13","symbol":"PHIO","fiscalQuarterEnding":"2025/09","expectedEps":-0.45,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1763010000000,"reportTimeType":"post","actualEps":-0.44},{"market":"US","date":"2025-08-14","symbol":"PHIO","fiscalQuarterEnding":"2025/06","expectedEps":-0.36,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1755144000000,"reportTimeType":"post","actualEps":-0.45},{"market":"US","date":"2025-05-15","symbol":"PHIO","fiscalQuarterEnding":"2025/03","expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1747281600000,"reportTimeType":"post","actualEps":-0.41},{"market":"US","date":"2025-03-31","symbol":"PHIO","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1743393600000,"reportTimeType":"post","actualEps":null},{"market":"US","date":"2024-11-14","symbol":"PHIO","fiscalQuarterEnding":"2024/09","expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1731560400000,"reportTimeType":"post","actualEps":-1.54}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"PHIO\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"PHIO\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":1,"updateTime":1740200400000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/PHIO\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"PHIO","date":"2025-12-12","current":-0.432035,"percent":0.289902,"low":-5.606854,"twenty":-1.789969,"median":-0.776088,"eighty":-0.326811,"high":-0.115258,"avg":-1.14526,"sd":1.034599,"marketCap":12271447},"quantilePoints":[{"date":"2020-12-18","current":-1.671432,"twenty":-1.498507,"median":-1.170071,"eighty":-0.754259,"marketCap":15029513},{"date":"2020-12-24","current":-1.735717,"twenty":-1.498507,"median":-1.170071,"eighty":-0.754259,"marketCap":15607571},{"date":"2020-12-31","current":-1.729289,"twenty":-1.498507,"median":-1.170071,"eighty":-0.754259,"marketCap":15549765},{"date":"2021-01-08","current":-1.954289,"twenty":-1.498507,"median":-1.170071,"eighty":-0.754259,"marketCap":17572969},{"date":"2021-01-15","current":-1.870718,"twenty":-1.498507,"median":-1.170071,"eighty":-0.754259,"marketCap":16821494},{"date":"2021-01-22","current":-1.857861,"twenty":-1.498507,"median":-1.170071,"eighty":-0.754259,"marketCap":16705882},{"date":"2021-01-29","current":-3.551126,"twenty":-1.498507,"median":-1.170071,"eighty":-0.754259,"marketCap":31931721},{"date":"2021-02-05","current":-3.755344,"twenty":-1.498507,"median":-1.170071,"eighty":-0.754259,"marketCap":33768050},{"date":"2021-02-12","current":-3.891489,"twenty":-1.498507,"median":-1.170071,"eighty":-0.754259,"marketCap":34992269},{"date":"2021-02-19","current":-5.385349,"twenty":-1.498507,"median":-1.170071,"eighty":-0.754259,"marketCap":48425057},{"date":"2021-02-26","current":-3.959408,"twenty":-1.498507,"median":-1.170071,"eighty":-0.754259,"marketCap":35602998},{"date":"2021-03-05","current":-3.502553,"twenty":-1.497101,"median":-1.169531,"eighty":-0.754151,"marketCap":31494960},{"date":"2021-03-12","current":-4.360887,"twenty":-1.497101,"median":-1.169531,"eighty":-0.754151,"marketCap":39213092},{"date":"2021-03-19","current":-4.180913,"twenty":-1.497101,"median":-1.169531,"eighty":-0.754151,"marketCap":37594774},{"date":"2021-03-26","current":-4.323942,"twenty":-1.498507,"median":-1.170071,"eighty":-0.754259,"marketCap":38024743},{"date":"2021-04-01","current":-4.231616,"twenty":-1.498507,"median":-1.170071,"eighty":-0.754259,"marketCap":37212827},{"date":"2021-04-09","current":-4.216228,"twenty":-1.497101,"median":-1.169531,"eighty":-0.754151,"marketCap":37077508},{"date":"2021-04-16","current":-3.523782,"twenty":-1.497101,"median":-1.169531,"eighty":-0.754151,"marketCap":30988135},{"date":"2021-04-23","current":-3.585332,"twenty":-1.497101,"median":-1.169531,"eighty":-0.754151,"marketCap":31529413},{"date":"2021-04-30","current":-3.5552,"twenty":-1.497101,"median":-1.169531,"eighty":-0.754151,"marketCap":31264430},{"date":"2021-05-07","current":-4.109257,"twenty":-1.498848,"median":-1.169531,"eighty":-0.754151,"marketCap":36136808},{"date":"2021-05-14","current":-2.624434,"twenty":-1.499955,"median":-1.169531,"eighty":-0.754151,"marketCap":25850675},{"date":"2021-05-21","current":-2.926725,"twenty":-1.501287,"median":-1.169531,"eighty":-0.754151,"marketCap":28828240},{"date":"2021-05-28","current":-3.050389,"twenty":-1.503829,"median":-1.169531,"eighty":-0.754151,"marketCap":30046334},{"date":"2021-06-04","current":-2.844282,"twenty":-1.504533,"median":-1.169531,"eighty":-0.754151,"marketCap":28016176},{"date":"2021-06-11","current":-3.036649,"twenty":-1.506728,"median":-1.169531,"eighty":-0.754151,"marketCap":29910991},{"date":"2021-06-18","current":-3.022908,"twenty":-1.511311,"median":-1.169531,"eighty":-0.754151,"marketCap":29775647},{"date":"2021-06-25","current":-3.325199,"twenty":-1.512072,"median":-1.169531,"eighty":-0.754151,"marketCap":32753212},{"date":"2021-07-02","current":-2.967946,"twenty":-1.512072,"median":-1.169531,"eighty":-0.754151,"marketCap":29234272},{"date":"2021-07-09","current":-2.858022,"twenty":-1.512072,"median":-1.169531,"eighty":-0.754151,"marketCap":28151520},{"date":"2021-07-16","current":-2.50077,"twenty":-1.512072,"median":-1.169531,"eighty":-0.754151,"marketCap":24632580},{"date":"2021-07-23","current":-2.583213,"twenty":-1.512072,"median":-1.169531,"eighty":-0.754151,"marketCap":25444644},{"date":"2021-07-30","current":-2.473289,"twenty":-1.512072,"median":-1.169531,"eighty":-0.754151,"marketCap":24361893},{"date":"2021-08-06","current":-2.473289,"twenty":-1.512072,"median":-1.169531,"eighty":-0.754151,"marketCap":24361893},{"date":"2021-08-13","current":-2.142581,"twenty":-1.512072,"median":-1.169531,"eighty":-0.754151,"marketCap":23279142},{"date":"2021-08-20","current":-2.10521,"twenty":-1.512072,"median":-1.169531,"eighty":-0.754151,"marketCap":22873111},{"date":"2021-08-27","current":-2.379261,"twenty":-1.512072,"median":-1.169531,"eighty":-0.754151,"marketCap":25850675},{"date":"2021-09-03","current":-2.528744,"twenty":-1.513652,"median":-1.169531,"eighty":-0.754151,"marketCap":27474801},{"date":"2021-09-10","current":-2.553658,"twenty":-1.517656,"median":-1.169531,"eighty":-0.754151,"marketCap":27745489},{"date":"2021-09-17","current":-2.840165,"twenty":-1.535231,"median":-1.169531,"eighty":-0.754151,"marketCap":30858397},{"date":"2021-09-24","current":-2.678226,"twenty":-1.55235,"median":-1.169531,"eighty":-0.754151,"marketCap":29098928},{"date":"2021-10-01","current":-2.478916,"twenty":-1.568375,"median":-1.169531,"eighty":-0.754151,"marketCap":26933426},{"date":"2021-10-08","current":-2.279606,"twenty":-1.575639,"median":-1.177333,"eighty":-0.754151,"marketCap":24767924},{"date":"2021-10-15","current":-2.080297,"twenty":-1.592553,"median":-1.179943,"eighty":-0.754151,"marketCap":22602423},{"date":"2021-10-22","current":-2.030469,"twenty":-1.605485,"median":-1.187834,"eighty":-0.757627,"marketCap":22061047},{"date":"2021-10-29","current":-2.092754,"twenty":-1.626655,"median":-1.191091,"eighty":-0.757651,"marketCap":22737767},{"date":"2021-11-05","current":-2.130124,"twenty":-1.639611,"median":-1.196448,"eighty":-0.757891,"marketCap":23143798},{"date":"2021-11-12","current":-1.727879,"twenty":-1.652657,"median":-1.202967,"eighty":-0.759558,"marketCap":21249455},{"date":"2021-11-19","current":-1.507767,"twenty":-1.654895,"median":-1.210405,"eighty":-0.760343,"marketCap":18542518},{"date":"2021-11-26","current":-1.529778,"twenty":-1.652657,"median":-1.212029,"eighty":-0.760343,"marketCap":18813211},{"date":"2021-12-03","current":-1.298661,"twenty":-1.652657,"median":-1.2135,"eighty":-0.760343,"marketCap":15970928},{"date":"2021-12-10","current":-1.353689,"twenty":-1.652657,"median":-1.217439,"eighty":-0.760343,"marketCap":16647662},{"date":"2021-12-17","current":-1.287655,"twenty":-1.652657,"median":-1.227086,"eighty":-0.761524,"marketCap":15835581},{"date":"2021-12-23","current":-1.298661,"twenty":-1.652657,"median":-1.228561,"eighty":-0.763642,"marketCap":15970928},{"date":"2021-12-31","current":-1.10056,"twenty":-1.652657,"median":-1.228561,"eighty":-0.77102,"marketCap":13534684},{"date":"2022-01-07","current":-1.063471,"twenty":-1.652486,"median":-1.228561,"eighty":-0.771783,"marketCap":13078565},{"date":"2022-01-14","current":-0.973005,"twenty":-1.652486,"median":-1.228561,"eighty":-0.773446,"marketCap":11966015},{"date":"2022-01-21","current":-0.946812,"twenty":-1.652486,"median":-1.228561,"eighty":-0.776821,"marketCap":11643889},{"date":"2022-01-28","current":-0.871643,"twenty":-1.652486,"median":-1.228561,"eighty":-0.781639,"marketCap":10719469},{"date":"2022-02-04","current":-0.985881,"twenty":-1.652486,"median":-1.228561,"eighty":-0.784351,"marketCap":12124370},{"date":"2022-02-11","current":-0.986432,"twenty":-1.652316,"median":-1.228561,"eighty":-0.78546,"marketCap":12131138},{"date":"2022-02-18","current":-0.917427,"twenty":-1.652316,"median":-1.228561,"eighty":-0.790609,"marketCap":11282513},{"date":"2022-02-25","current":-0.928542,"twenty":-1.652316,"median":-1.228561,"eighty":-0.794492,"marketCap":11419214},{"date":"2022-03-04","current":-0.891013,"twenty":-1.652316,"median":-1.228561,"eighty":-0.797055,"marketCap":10957680},{"date":"2022-03-11","current":-0.847211,"twenty":-1.652316,"median":-1.228561,"eighty":-0.798197,"marketCap":10419000},{"date":"2022-03-18","current":-0.934375,"twenty":-1.652316,"median":-1.228561,"eighty":-0.802126,"marketCap":11490947},{"date":"2022-03-25","current":-0.921076,"twenty":-1.652316,"median":-1.228561,"eighty":-0.806184,"marketCap":12238333},{"date":"2022-04-01","current":-0.890312,"twenty":-1.646585,"median":-1.228151,"eighty":-0.808371,"marketCap":11829577},{"date":"2022-04-08","current":-2.39386,"twenty":-1.639396,"median":-1.224535,"eighty":-0.808371,"marketCap":31807215},{"date":"2022-04-14","current":-1.21221,"twenty":-1.639396,"median":-1.220432,"eighty":-0.808371,"marketCap":16106631},{"date":"2022-04-22","current":-1.283516,"twenty":-1.639396,"median":-1.220432,"eighty":-0.808371,"marketCap":17054081},{"date":"2022-04-29","current":-0.855881,"twenty":-1.639396,"median":-1.214647,"eighty":-0.808371,"marketCap":11372094},{"date":"2022-05-06","current":-0.870346,"twenty":-1.639396,"median":-1.212174,"eighty":-0.808371,"marketCap":11564291},{"date":"2022-05-13","current":-0.771725,"twenty":-1.639396,"median":-1.212137,"eighty":-0.803488,"marketCap":9663542},{"date":"2022-05-20","current":-0.723513,"twenty":-1.639396,"median":-1.206863,"eighty":-0.801113,"marketCap":9059827},{"date":"2022-05-27","current":-0.796268,"twenty":-1.639396,"median":-1.201104,"eighty":-0.797537,"marketCap":9970863},{"date":"2022-06-03","current":-0.839026,"twenty":-1.639396,"median":-1.198734,"eighty":-0.797167,"marketCap":10506284},{"date":"2022-06-10","current":-0.780888,"twenty":-1.639396,"median":-1.193559,"eighty":-0.796536,"marketCap":9778275},{"date":"2022-06-17","current":-0.729621,"twenty":-1.639396,"median":-1.184786,"eighty":-0.793918,"marketCap":9136315},{"date":"2022-06-24","current":-0.740965,"twenty":-1.639504,"median":-1.17781,"eighty":-0.790818,"marketCap":9278366},{"date":"2022-07-01","current":-0.767253,"twenty":-1.639504,"median":-1.17061,"eighty":-0.788511,"marketCap":9607541},{"date":"2022-07-08","current":-0.801831,"twenty":-1.639504,"median":-1.167786,"eighty":-0.787642,"marketCap":10040522},{"date":"2022-07-15","current":-0.771399,"twenty":-1.639504,"median":-1.158325,"eighty":-0.786964,"marketCap":9659458},{"date":"2022-07-22","current":-0.784051,"twenty":-1.639504,"median":-1.151485,"eighty":-0.78508,"marketCap":9817885},{"date":"2022-07-29","current":-0.780015,"twenty":-1.639504,"median":-1.145238,"eighty":-0.783179,"marketCap":9767348},{"date":"2022-08-05","current":-0.785578,"twenty":-1.639504,"median":-1.142726,"eighty":-0.781191,"marketCap":9837007},{"date":"2022-08-12","current":-0.817469,"twenty":-1.639504,"median":-1.133577,"eighty":-0.781191,"marketCap":10108816},{"date":"2022-08-19","current":-0.795488,"twenty":-1.639504,"median":-1.124069,"eighty":-0.781191,"marketCap":9837007},{"date":"2022-08-26","current":-0.763346,"twenty":-1.639504,"median":-1.118863,"eighty":-0.778622,"marketCap":9439539},{"date":"2022-09-02","current":-0.760806,"twenty":-1.639504,"median":-1.112659,"eighty":-0.776493,"marketCap":9408124},{"date":"2022-09-09","current":-0.793831,"twenty":-1.639504,"median":-1.110534,"eighty":-0.775608,"marketCap":9816519},{"date":"2022-09-16","current":-0.751086,"twenty":-1.639504,"median":-1.101669,"eighty":-0.77548,"marketCap":9287927},{"date":"2022-09-23","current":-0.678959,"twenty":-1.639504,"median":-1.09706,"eighty":-0.773926,"marketCap":8396012},{"date":"2022-09-30","current":-0.631022,"twenty":-1.639504,"median":-1.091535,"eighty":-0.773184,"marketCap":7803224},{"date":"2022-10-07","current":-0.613019,"twenty":-1.639504,"median":-1.084943,"eighty":-0.772177,"marketCap":7580587},{"date":"2022-10-14","current":-0.61578,"twenty":-1.639504,"median":-1.078622,"eighty":-0.771783,"marketCap":7614734},{"date":"2022-10-21","current":-0.641847,"twenty":-1.639504,"median":-1.066994,"eighty":-0.771127,"marketCap":7937079},{"date":"2022-10-28","current":-0.646376,"twenty":-1.639504,"median":-1.055575,"eighty":-0.767034,"marketCap":7993080},{"date":"2022-11-04","current":-0.619646,"twenty":-1.639504,"median":-1.037137,"eighty":-0.763737,"marketCap":7662539},{"date":"2022-11-11","current":-0.53798,"twenty":-1.639504,"median":-1.032527,"eighty":-0.7629,"marketCap":6563358},{"date":"2022-11-18","current":-0.44813,"twenty":-1.639504,"median":-1.023521,"eighty":-0.761465,"marketCap":5467186},{"date":"2022-11-25","current":-0.45362,"twenty":-1.639504,"median":-1.020329,"eighty":-0.759288,"marketCap":5534159},{"date":"2022-12-02","current":-0.445105,"twenty":-1.631759,"median":-1.011325,"eighty":-0.755853,"marketCap":5430283},{"date":"2022-12-09","current":-0.439027,"twenty":-1.631759,"median":-0.999192,"eighty":-0.753074,"marketCap":5356134},{"date":"2022-12-16","current":-0.426844,"twenty":-1.631759,"median":-0.992495,"eighty":-0.75098,"marketCap":5207495},{"date":"2022-12-23","current":-0.401525,"twenty":-1.631759,"median":-0.985881,"eighty":-0.747725,"marketCap":4898599},{"date":"2022-12-30","current":-0.416761,"twenty":-1.631759,"median":-0.979938,"eighty":-0.745379,"marketCap":5084483},{"date":"2023-01-06","current":-0.683398,"twenty":-1.631759,"median":-0.977213,"eighty":-0.742198,"marketCap":8337460},{"date":"2023-01-13","current":-0.60363,"twenty":-1.631759,"median":-0.977213,"eighty":-0.740355,"marketCap":7364287},{"date":"2023-01-20","current":-0.592652,"twenty":-1.631759,"median":-0.977213,"eighty":-0.737547,"marketCap":7230355},{"date":"2023-01-27","current":-0.581635,"twenty":-1.631759,"median":-0.977213,"eighty":-0.734106,"marketCap":7095951},{"date":"2023-02-03","current":-0.616179,"twenty":-1.631759,"median":-0.977213,"eighty":-0.729024,"marketCap":7517380},{"date":"2023-02-10","current":-0.515331,"twenty":-1.631759,"median":-0.977213,"eighty":-0.729024,"marketCap":6287035},{"date":"2023-02-17","current":-0.489209,"twenty":-1.631759,"median":-0.977213,"eighty":-0.729024,"marketCap":5968344},{"date":"2023-02-24","current":-0.480806,"twenty":-1.631759,"median":-0.977213,"eighty":-0.729024,"marketCap":5865834},{"date":"2023-03-03","current":-0.560162,"twenty":-1.631759,"median":-0.977213,"eighty":-0.729024,"marketCap":6833982},{"date":"2023-03-10","current":-0.516031,"twenty":-1.631759,"median":-0.977213,"eighty":-0.728426,"marketCap":6295578},{"date":"2023-03-17","current":-0.535889,"twenty":-1.631759,"median":-0.977068,"eighty":-0.726171,"marketCap":6537842},{"date":"2023-03-24","current":-0.572334,"twenty":-1.631759,"median":-0.977068,"eighty":-0.71795,"marketCap":6570398},{"date":"2023-03-31","current":-0.563264,"twenty":-1.629249,"median":-0.975604,"eighty":-0.717167,"marketCap":6466270},{"date":"2023-04-06","current":-0.5793,"twenty":-1.629249,"median":-0.975604,"eighty":-0.714469,"marketCap":6650363},{"date":"2023-04-14","current":-0.505134,"twenty":-1.631759,"median":-0.973005,"eighty":-0.711472,"marketCap":5798933},{"date":"2023-04-21","current":-0.539966,"twenty":-1.631759,"median":-0.973005,"eighty":-0.704091,"marketCap":6198807},{"date":"2023-04-28","current":-0.423323,"twenty":-1.631759,"median":-0.973005,"eighty":-0.701367,"marketCap":4859744},{"date":"2023-05-05","current":-0.509822,"twenty":-1.631759,"median":-0.973005,"eighty":-0.697146,"marketCap":5852757},{"date":"2023-05-12","current":-0.510477,"twenty":-1.631759,"median":-0.9686,"eighty":-0.690766,"marketCap":5860280},{"date":"2023-05-19","current":-0.610776,"twenty":-1.631759,"median":-0.967994,"eighty":-0.681773,"marketCap":7598053},{"date":"2023-05-26","current":-0.454756,"twenty":-1.631759,"median":-0.965521,"eighty":-0.67868,"marketCap":5657164},{"date":"2023-06-02","current":-0.408797,"twenty":-1.631759,"median":-0.96266,"eighty":-0.676522,"marketCap":5085429},{"date":"2023-06-09","current":-0.431758,"twenty":-1.631759,"median":-0.958147,"eighty":-0.664276,"marketCap":5371071},{"date":"2023-06-16","current":-0.456909,"twenty":-1.631759,"median":-0.954712,"eighty":-0.657282,"marketCap":5683949},{"date":"2023-06-23","current":-0.419183,"twenty":-1.634269,"median":-0.944146,"eighty":-0.654729,"marketCap":5214633},{"date":"2023-06-30","current":-0.392634,"twenty":-1.636779,"median":-0.938527,"eighty":-0.648646,"marketCap":4884372},{"date":"2023-07-07","current":-0.419183,"twenty":-1.636779,"median":-0.938527,"eighty":-0.644655,"marketCap":5214633},{"date":"2023-07-14","current":-0.38984,"twenty":-1.636779,"median":-0.937013,"eighty":-0.639638,"marketCap":4849608},{"date":"2023-07-21","current":-0.370977,"twenty":-1.636779,"median":-0.937013,"eighty":-0.633655,"marketCap":4614950},{"date":"2023-07-28","current":-0.375867,"twenty":-1.636779,"median":-0.937013,"eighty":-0.631022,"marketCap":4675787},{"date":"2023-08-04","current":-0.353511,"twenty":-1.639289,"median":-0.93777,"eighty":-0.629587,"marketCap":4397673},{"date":"2023-08-11","current":-0.318579,"twenty":-1.639289,"median":-0.93777,"eighty":-0.624064,"marketCap":3963121},{"date":"2023-08-18","current":-0.406633,"twenty":-1.639289,"median":-0.93777,"eighty":-0.621893,"marketCap":5065831},{"date":"2023-08-25","current":-0.413767,"twenty":-1.639289,"median":-0.93777,"eighty":-0.619457,"marketCap":5154705},{"date":"2023-09-01","current":-0.379881,"twenty":-1.639289,"median":-0.93777,"eighty":-0.610776,"marketCap":4732553},{"date":"2023-09-08","current":-0.401282,"twenty":-1.639396,"median":-0.938527,"eighty":-0.608865,"marketCap":4999176},{"date":"2023-09-15","current":-0.311217,"twenty":-1.639504,"median":-0.939799,"eighty":-0.604931,"marketCap":3877138},{"date":"2023-09-22","current":-0.249687,"twenty":-1.639504,"median":-0.939799,"eighty":-0.602435,"marketCap":3110598},{"date":"2023-09-29","current":-0.262171,"twenty":-1.639504,"median":-0.939799,"eighty":-0.598474,"marketCap":3266128},{"date":"2023-10-06","current":-0.260388,"twenty":-1.639504,"median":-0.939799,"eighty":-0.598474,"marketCap":3243909},{"date":"2023-10-13","current":-0.313892,"twenty":-1.639504,"median":-0.939799,"eighty":-0.598474,"marketCap":3910466},{"date":"2023-10-20","current":-0.244336,"twenty":-1.639504,"median":-0.939799,"eighty":-0.598474,"marketCap":3043942},{"date":"2023-10-27","current":-0.226502,"twenty":-1.639826,"median":-0.942079,"eighty":-0.600181,"marketCap":2821757},{"date":"2023-11-03","current":-0.222578,"twenty":-1.639826,"median":-0.942079,"eighty":-0.600181,"marketCap":2772876},{"date":"2023-11-10","current":-0.181915,"twenty":-1.639826,"median":-0.942079,"eighty":-0.600181,"marketCap":2266293},{"date":"2023-11-17","current":-0.205332,"twenty":-1.639826,"median":-0.942079,"eighty":-0.597918,"marketCap":2394578},{"date":"2023-11-24","current":-0.196951,"twenty":-1.639826,"median":-0.942079,"eighty":-0.591142,"marketCap":2296840},{"date":"2023-12-01","current":-0.229112,"twenty":-1.639826,"median":-0.942079,"eighty":-0.581635,"marketCap":2671909},{"date":"2023-12-08","current":-0.19276,"twenty":-1.639719,"median":-0.941575,"eighty":-0.578835,"marketCap":2247971},{"date":"2023-12-15","current":-0.155046,"twenty":-1.639719,"median":-0.941575,"eighty":-0.573898,"marketCap":1808150},{"date":"2023-12-22","current":-0.16106,"twenty":-1.639719,"median":-0.941575,"eighty":-0.569388,"marketCap":1878277},{"date":"2023-12-29","current":-0.160075,"twenty":-1.639826,"median":-0.942079,"eighty":-0.563264,"marketCap":1866793},{"date":"2024-01-05","current":-0.159656,"twenty":-1.640714,"median":-0.944146,"eighty":-0.559038,"marketCap":1861906},{"date":"2024-01-12","current":-0.146644,"twenty":-1.640714,"median":-0.944146,"eighty":-0.544651,"marketCap":1710168},{"date":"2024-01-19","current":-0.138285,"twenty":-1.641601,"median":-0.946213,"eighty":-0.539172,"marketCap":1612675},{"date":"2024-01-26","current":-0.125713,"twenty":-1.640714,"median":-0.944146,"eighty":-0.534718,"marketCap":1466068},{"date":"2024-02-02","current":-0.127599,"twenty":-1.640714,"median":-0.944146,"eighty":-0.52585,"marketCap":1488059},{"date":"2024-02-09","current":-0.127348,"twenty":-1.640714,"median":-0.944146,"eighty":-0.522459,"marketCap":1485127},{"date":"2024-02-16","current":-0.136189,"twenty":-1.640714,"median":-0.944146,"eighty":-0.51385,"marketCap":1588240},{"date":"2024-02-23","current":-0.178077,"twenty":-1.640714,"median":-0.944146,"eighty":-0.512362,"marketCap":2076736},{"date":"2024-03-01","current":-0.226284,"twenty":-1.639826,"median":-0.942079,"eighty":-0.508511,"marketCap":2638922},{"date":"2024-03-08","current":-0.184798,"twenty":-1.639826,"median":-0.942079,"eighty":-0.503269,"marketCap":2155120},{"date":"2024-03-15","current":-0.197244,"twenty":-1.639826,"median":-0.935928,"eighty":-0.492183,"marketCap":2300261},{"date":"2024-03-22","current":-0.175999,"twenty":-1.639826,"median":-0.928542,"eighty":-0.488621,"marketCap":2052495},{"date":"2024-03-28","current":-0.152134,"twenty":-1.639826,"median":-0.921076,"eighty":-0.486408,"marketCap":1774186},{"date":"2024-04-05","current":-0.156456,"twenty":-1.640714,"median":-0.916562,"eighty":-0.480806,"marketCap":1693797},{"date":"2024-04-12","current":-0.296683,"twenty":-1.640714,"median":-0.91096,"eighty":-0.469768,"marketCap":3211894},{"date":"2024-04-19","current":-0.270514,"twenty":-1.640714,"median":-0.906077,"eighty":-0.458759,"marketCap":2928586},{"date":"2024-04-26","current":-0.29944,"twenty":-1.639826,"median":-0.902569,"eighty":-0.45362,"marketCap":3241740},{"date":"2024-05-03","current":-0.329002,"twenty":-1.639826,"median":-0.896424,"eighty":-0.44813,"marketCap":3561781},{"date":"2024-05-10","current":-0.326585,"twenty":-1.639826,"median":-0.890312,"eighty":-0.445105,"marketCap":3535609},{"date":"2024-05-17","current":-0.358601,"twenty":-1.639826,"median":-0.880558,"eighty":-0.440142,"marketCap":3362961},{"date":"2024-05-24","current":-0.375934,"twenty":-1.639826,"median":-0.869368,"eighty":-0.436591,"marketCap":3525507},{"date":"2024-05-31","current":-0.368247,"twenty":-1.639826,"median":-0.863934,"eighty":-0.431758,"marketCap":3453417},{"date":"2024-06-07","current":-0.367218,"twenty":-1.639826,"median":-0.848175,"eighty":-0.425948,"marketCap":3443775},{"date":"2024-06-14","current":-0.357426,"twenty":-1.640714,"median":-0.843753,"eighty":-0.421762,"marketCap":3351941},{"date":"2024-06-21","current":-0.349053,"twenty":-1.641601,"median":-0.832901,"eighty":-0.419183,"marketCap":3273422},{"date":"2024-06-28","current":-0.337449,"twenty":-1.644264,"median":-0.825843,"eighty":-0.417785,"marketCap":3164595},{"date":"2024-07-05","current":-0.284373,"twenty":-1.644264,"median":-0.821822,"eighty":-0.414991,"marketCap":2666854},{"date":"2024-07-12","current":-0.317983,"twenty":-1.644264,"median":-0.816685,"eighty":-0.411983,"marketCap":2982048},{"date":"2024-07-15","current":-0.274733,"twenty":-1.644264,"median":-0.812746,"eighty":-0.410799,"marketCap":2576449},{"date":"2024-08-02","current":-0.161304,"twenty":-1.655347,"median":-0.803629,"eighty":-0.407754,"marketCap":1512707},{"date":"2024-08-09","current":-0.143079,"twenty":-1.655347,"median":-0.80079,"eighty":-0.40521,"marketCap":1341794},{"date":"2024-08-16","current":-0.151733,"twenty":-1.655347,"median":-0.798197,"eighty":-0.402675,"marketCap":1316285},{"date":"2024-08-23","current":-0.303609,"twenty":-1.655347,"median":-0.796603,"eighty":-0.395988,"marketCap":2633806},{"date":"2024-08-30","current":-0.261937,"twenty":-1.655347,"median":-0.793831,"eighty":-0.391029,"marketCap":2272303},{"date":"2024-09-06","current":-0.260945,"twenty":-1.655347,"median":-0.789855,"eighty":-0.385648,"marketCap":2263696},{"date":"2024-09-13","current":-0.287734,"twenty":-1.655347,"median":-0.786887,"eighty":-0.381456,"marketCap":2496090},{"date":"2024-09-20","current":-0.352226,"twenty":-1.655347,"median":-0.781191,"eighty":-0.37873,"marketCap":3055559},{"date":"2024-09-27","current":-0.35421,"twenty":-1.655347,"median":-0.779362,"eighty":-0.374682,"marketCap":3072773},{"date":"2024-10-04","current":-0.313531,"twenty":-1.655347,"median":-0.775543,"eighty":-0.372417,"marketCap":2719878},{"date":"2024-10-11","current":-0.253007,"twenty":-1.655347,"median":-0.773907,"eighty":-0.36763,"marketCap":2194838},{"date":"2024-10-18","current":-0.262929,"twenty":-1.655347,"median":-0.773508,"eighty":-0.363792,"marketCap":2280910},{"date":"2024-10-25","current":-0.293687,"twenty":-1.655347,"median":-0.773177,"eighty":-0.357426,"marketCap":2547734},{"date":"2024-10-31","current":-0.312538,"twenty":-1.655347,"median":-0.772052,"eighty":-0.353511,"marketCap":2711271},{"date":"2024-11-08","current":-0.32246,"twenty":-1.65613,"median":-0.770744,"eighty":-0.35155,"marketCap":2797343},{"date":"2024-11-15","current":-0.221257,"twenty":-1.65613,"median":-0.76436,"eighty":-0.347708,"marketCap":1919407},{"date":"2024-11-22","current":-0.29352,"twenty":-1.65613,"median":-0.76436,"eighty":-0.344977,"marketCap":2177624},{"date":"2024-11-29","current":-0.386871,"twenty":-1.65613,"median":-0.76436,"eighty":-0.339518,"marketCap":2870195},{"date":"2024-12-06","current":-0.385449,"twenty":-1.65613,"median":-0.76436,"eighty":-0.339518,"marketCap":2859643},{"date":"2024-12-13","current":-0.408362,"twenty":-1.65613,"median":-0.76436,"eighty":-0.339518,"marketCap":3029639},{"date":"2024-12-20","current":-0.247484,"twenty":-1.65613,"median":-0.76436,"eighty":-0.339311,"marketCap":1836081},{"date":"2024-12-27","current":-0.297265,"twenty":-1.65613,"median":-0.76436,"eighty":-0.337364,"marketCap":2205407},{"date":"2025-01-03","current":-0.270241,"twenty":-1.65613,"median":-0.763489,"eighty":-0.332534,"marketCap":2004916},{"date":"2025-01-10","current":-0.240372,"twenty":-1.656913,"median":-0.762021,"eighty":-0.326962,"marketCap":1783320},{"date":"2025-01-17","current":-0.831105,"twenty":-1.656913,"median":-0.760806,"eighty":-0.326585,"marketCap":6165966},{"date":"2025-01-24","current":-0.881902,"twenty":-1.656913,"median":-0.760806,"eighty":-0.326585,"marketCap":6542829},{"date":"2025-01-31","current":-0.836676,"twenty":-1.656913,"median":-0.7613,"eighty":-0.326585,"marketCap":6207299},{"date":"2025-02-07","current":-0.931978,"twenty":-1.656913,"median":-0.762021,"eighty":-0.326585,"marketCap":6914344},{"date":"2025-02-14","current":-0.821793,"twenty":-1.656913,"median":-0.763435,"eighty":-0.326962,"marketCap":6096884},{"date":"2025-02-21","current":-0.789656,"twenty":-1.656913,"median":-0.765835,"eighty":-0.326962,"marketCap":5858459},{"date":"2025-02-28","current":-0.920729,"twenty":-1.656913,"median":-0.768837,"eighty":-0.326962,"marketCap":6830892},{"date":"2025-03-07","current":-0.862782,"twenty":-1.657245,"median":-0.771897,"eighty":-0.326887,"marketCap":6400976},{"date":"2025-03-14","current":-0.856343,"twenty":-1.657245,"median":-0.773343,"eighty":-0.326887,"marketCap":6353207},{"date":"2025-03-21","current":-0.856343,"twenty":-1.657245,"median":-0.775465,"eighty":-0.326887,"marketCap":6353207},{"date":"2025-03-28","current":-0.843465,"twenty":-1.657245,"median":-0.777869,"eighty":-0.326887,"marketCap":6257670},{"date":"2025-04-04","current":-0.781666,"twenty":-1.657245,"median":-0.779906,"eighty":-0.326887,"marketCap":5588912},{"date":"2025-04-11","current":-1.102651,"twenty":-1.656913,"median":-0.776375,"eighty":-0.326962,"marketCap":7883954},{"date":"2025-04-17","current":-1.804338,"twenty":-1.658575,"median":-0.776375,"eighty":-0.326962,"marketCap":12901015},{"date":"2025-04-25","current":-1.490249,"twenty":-1.66359,"median":-0.776231,"eighty":-0.326887,"marketCap":10655283},{"date":"2025-05-02","current":-1.263037,"twenty":-1.66359,"median":-0.776231,"eighty":-0.326887,"marketCap":9030711},{"date":"2025-05-09","current":-1.202892,"twenty":-1.66359,"median":-0.776231,"eighty":-0.326887,"marketCap":8600677},{"date":"2025-05-16","current":-1.189526,"twenty":-1.66359,"median":-0.776231,"eighty":-0.326887,"marketCap":8505114},{"date":"2025-05-23","current":-1.299601,"twenty":-1.66359,"median":-0.776231,"eighty":-0.326887,"marketCap":8791803},{"date":"2025-05-30","current":-1.440862,"twenty":-1.66359,"median":-0.776231,"eighty":-0.326887,"marketCap":9747434},{"date":"2025-06-06","current":-1.73751,"twenty":-1.666289,"median":-0.776231,"eighty":-0.326887,"marketCap":11754258},{"date":"2025-06-13","current":-1.751876,"twenty":-1.679146,"median":-0.776231,"eighty":-0.326887,"marketCap":11851440},{"date":"2025-06-20","current":-1.673857,"twenty":-1.686968,"median":-0.776088,"eighty":-0.326811,"marketCap":11323643},{"date":"2025-06-27","current":-1.567468,"twenty":-1.686968,"median":-0.776088,"eighty":-0.326811,"marketCap":10603920},{"date":"2025-07-03","current":-1.702227,"twenty":-1.691978,"median":-0.776088,"eighty":-0.326811,"marketCap":11515569},{"date":"2025-07-11","current":-1.734144,"twenty":-1.707909,"median":-0.776088,"eighty":-0.326811,"marketCap":11731486},{"date":"2025-07-18","current":-1.723505,"twenty":-1.719261,"median":-0.776088,"eighty":-0.326811,"marketCap":11659514},{"date":"2025-07-25","current":-1.780246,"twenty":-1.733339,"median":-0.776088,"eighty":-0.326811,"marketCap":12043366},{"date":"2025-08-01","current":-1.688042,"twenty":-1.737582,"median":-0.776088,"eighty":-0.326811,"marketCap":11419606},{"date":"2025-08-08","current":-1.595838,"twenty":-1.737582,"median":-0.776088,"eighty":-0.326811,"marketCap":10795846},{"date":"2025-08-15","current":-1.553283,"twenty":-1.734773,"median":-0.776088,"eighty":-0.326811,"marketCap":10507957},{"date":"2025-08-22","current":-1.673165,"twenty":-1.737582,"median":-0.776088,"eighty":-0.326811,"marketCap":11854372},{"date":"2025-08-29","current":-1.600418,"twenty":-1.737582,"median":-0.776088,"eighty":-0.326811,"marketCap":11338965},{"date":"2025-09-05","current":-1.665082,"twenty":-1.737619,"median":-0.77587,"eighty":-0.326736,"marketCap":11797105},{"date":"2025-09-12","current":-1.875238,"twenty":-1.740189,"median":-0.776088,"eighty":-0.326811,"marketCap":13286060},{"date":"2025-09-19","current":-1.705496,"twenty":-1.748297,"median":-0.776088,"eighty":-0.326811,"marketCap":12083442},{"date":"2025-09-26","current":-1.778243,"twenty":-1.758968,"median":-0.776088,"eighty":-0.326811,"marketCap":12598850},{"date":"2025-10-03","current":-1.931818,"twenty":-1.768898,"median":-0.776088,"eighty":-0.326811,"marketCap":13686932},{"date":"2025-10-10","current":-1.90757,"twenty":-1.784533,"median":-0.776088,"eighty":-0.326811,"marketCap":13515130},{"date":"2025-10-17","current":-1.713579,"twenty":-1.794111,"median":-0.776088,"eighty":-0.326811,"marketCap":12140710},{"date":"2025-10-24","current":-1.729745,"twenty":-1.794111,"median":-0.776088,"eighty":-0.326811,"marketCap":12255245},{"date":"2025-10-31","current":-1.665082,"twenty":-1.794111,"median":-0.776088,"eighty":-0.326811,"marketCap":11797105},{"date":"2025-11-07","current":-1.196272,"twenty":-1.794111,"median":-0.776088,"eighty":-0.326811,"marketCap":8475590},{"date":"2025-11-14","current":-1.155858,"twenty":-1.794111,"median":-0.776088,"eighty":-0.326811,"marketCap":8189252},{"date":"2025-11-21","current":-1.610671,"twenty":-1.794111,"median":-0.776088,"eighty":-0.326811,"marketCap":12809669},{"date":"2025-11-28","current":-1.705417,"twenty":-1.794111,"median":-0.776088,"eighty":-0.326811,"marketCap":13563179},{"date":"2025-12-05","current":-1.827232,"twenty":-1.794418,"median":-0.776088,"eighty":-0.326811,"marketCap":14531977},{"date":"2025-12-12","current":-1.542996,"twenty":-1.789969,"median":-0.776088,"eighty":-0.326811,"marketCap":12271447}],"updateTime":1765843541907},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"PHIO\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2586401960","title":"Phio Pharmaceuticals Completes Enrollment for PH-762 Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2586401960","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586401960?lang=en_us&edition=fundamental","pubTime":"2025-11-26 05:27","pubTimestamp":1764106057,"startTime":"0","endTime":"0","summary":"Phio Pharmaceuticals ( ($PHIO) ) has provided an announcement. On November 25, 2025, Phio Pharmaceuticals announced the completion of patient enrol...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/phio-pharmaceuticals-completes-enrollment-for-ph-762-trial?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/phio-pharmaceuticals-completes-enrollment-for-ph-762-trial?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4580","PHIO","LU1988902786.USD","LU1064131342.USD","BK4588","LU1989772840.SGD","BK4139","LU0320765489.SGD","LU0256863811.USD","LU0417517546.SGD","LU1989772923.USD","PH","BK4161","LU0211331839.USD","BK4585","LU2264538146.SGD","LU0256863902.USD","LU0070302665.USD","LU0208291251.USD"],"gpt_icon":0},{"id":"2586477413","title":"Phio Pharmaceuticals Completes Phase 1b Enrollment for PH-762 Skin Cancer Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2586477413","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586477413?lang=en_us&edition=fundamental","pubTime":"2025-11-26 00:31","pubTimestamp":1764088261,"startTime":"0","endTime":"0","summary":"Phio Pharmaceuticals Corp. has announced the completion of enrollment in its Phase 1b clinical trial of PH-762, an INTASYL siRNA compound designed to silence the PD-1 gene implicated in various forms of skin cancer. The trial is evaluating the safety and tolerability of neoadjuvant intratumoral PH-762 in patients with cutaneous squamous cell carcinoma , melanoma, and Merkel cell carcinoma. To date, 18 patients have completed treatment across five dose-escalating cohorts. Pathology results for the highest dose cohort are expected in Q1 2026. No dose-limiting toxicities or clinically relevant treatment-emergent adverse effects have been observed so far.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Phio Pharmaceuticals Corp. published t","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251125:nNDL94q63P:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PHIO","BK4139"],"gpt_icon":0},{"id":"2586491199","title":"Phio Pharmaceuticals CEO Robert J. Bitterman Reports Acquisition of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2586491199","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586491199?lang=en_us&edition=fundamental","pubTime":"2025-11-25 01:54","pubTimestamp":1764006880,"startTime":"0","endTime":"0","summary":"Robert J. Bitterman, Chairman, President, and CEO of Phio Pharmaceuticals Corp., reported the acquisition of common shares of Phio Pharmaceuticals Corp. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Phio Pharmaceuticals Corp. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on November 24, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251124:nNDL4sJNYr:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Phio Pharmaceuticals CEO Robert J. Bitterman Reports Acquisition of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PHIO","BK4139"],"gpt_icon":0},{"id":"2585616852","title":"BRIEF-Phio Pharmaceuticals Corp Files For Offering Of Up To 11.8 Million Common Shares By The Selling Stockholders - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2585616852","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585616852?lang=en_us&edition=fundamental","pubTime":"2025-11-21 05:44","pubTimestamp":1763675056,"startTime":"0","endTime":"0","summary":"BRIEF-Phio Pharmaceuticals Corp Files For Offering Of Up To 11.8 Million Common Shares By The Selling Stockholders - SEC FilingNov 20  - Phio Pharmaceuticals Corp PHIO.O:PHIO PHARMACEUTICALS CORP FILES FOR OFFERING OF UP TO 11.8 MILLION COMMON SHARES BY THE SELLING STOCKHOLDERS - SEC FILINGFurther company coverage: PHIO.O ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251120:nFWN3WW124:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PHIO"],"gpt_icon":0},{"id":"2585150601","title":"Phio Pharmaceuticals files to sell 11.76M shares of common stock for holders","url":"https://stock-news.laohu8.com/highlight/detail?id=2585150601","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585150601?lang=en_us&edition=fundamental","pubTime":"2025-11-21 05:11","pubTimestamp":1763673071,"startTime":"0","endTime":"0","summary":"The company will not receive any of the proceeds from the sale by the selling stockholders of the shares of common stock. Published first on TheFly...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/phio-pharmaceuticals-files-to-sell-11-76m-shares-of-common-stock-for-holders-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/phio-pharmaceuticals-files-to-sell-11-76m-shares-of-common-stock-for-holders-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PHIO","BK4139"],"gpt_icon":0},{"id":"2585761157","title":"Phio Pharmaceuticals Corp Files for Offering of up to 11.8 Mln Common Shares by the Selling Stockholders - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2585761157","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585761157?lang=en_us&edition=fundamental","pubTime":"2025-11-21 05:07","pubTimestamp":1763672830,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251120:nFWN3WW124:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","PHIO"],"gpt_icon":0},{"id":"2584089922","title":"Phio Pharmaceuticals CEO Robert J. Bitterman Acquires Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2584089922","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584089922?lang=en_us&edition=fundamental","pubTime":"2025-11-20 01:48","pubTimestamp":1763574498,"startTime":"0","endTime":"0","summary":"Robert J. Bitterman, Chairman, President & CEO of Phio Pharmaceuticals Corp., reported an acquisition of common shares of Phio Pharmaceuticals Corp. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Phio Pharmaceuticals Corp. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on November 19, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251119:nNDLqVrvh:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Phio Pharmaceuticals CEO Robert J. Bitterman Acquires Common Shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PHIO","BK4139"],"gpt_icon":0},{"id":"2584629877","title":"Phio Pharmaceuticals to Present INTASYL siRNA Technology at Advanced Therapies USA Congress","url":"https://stock-news.laohu8.com/highlight/detail?id=2584629877","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584629877?lang=en_us&edition=fundamental","pubTime":"2025-11-17 21:46","pubTimestamp":1763387160,"startTime":"0","endTime":"0","summary":"Phio Pharmaceuticals Corp. will deliver a podium presentation on its INTASYL siRNA drug technology at the Advanced Therapies USA 2025 Congress, taking place at the Pennsylvania Convention Center in Philadelphia on November 18-19, 2025. The presentation will focus on INTASYL's approach to down-regulating gene expression for cancer treatment.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Phio Pharmaceuticals Corp. published the original content used to generate this news brief via Newsfile  on November 17, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251117:nNDL1LcHVH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PHIO","BK4139"],"gpt_icon":0},{"id":"2583126315","title":"Phio Pharma Q3 EPS $(0.44) Misses $(0.40) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2583126315","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583126315?lang=en_us&edition=fundamental","pubTime":"2025-11-14 05:23","pubTimestamp":1763069002,"startTime":"0","endTime":"0","summary":"Phio Pharma (NASDAQ:PHIO) reported quarterly losses of $(0.44) per share which missed the analyst consensus estimate of $(0.40) by 10 percent. This is a 71.43 percent increase over losses of $(1.54) per share from the","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/11/48851032/phio-pharma-q3-eps-0-44-misses-0-40-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MNQmain","NVIW.SI",".IXIC","QLD","SQQQ","NQmain","TQQQ","PSQ","TSYW.SI","USJW.SI","QID","BK4139","PHIO","USAW.SI"],"gpt_icon":0},{"id":"2583512597","title":"Phio Pharmaceuticals Reports Positive PH-762 Skin Cancer Trial Results and Extends Cash Runway Into 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2583512597","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583512597?lang=en_us&edition=fundamental","pubTime":"2025-11-14 05:20","pubTimestamp":1763068807,"startTime":"0","endTime":"0","summary":"Phio Pharmaceuticals Corp. announced its third quarter 2025 financial results and provided a business update. The company reported progress in its Phase 1b clinical trial of INTASYL PH-762 for skin cancer, advancing to the fifth and final cohort at the maximum dose. At this dose, one patient achieved 100% tumor clearance , a second patient had greater than 90% tumor clearance , and a third patient showed greater than 50% tumor clearance . No dose-limiting toxicities or clinically relevant treatment-emergent adverse effects were observed, and PH-762 was well tolerated across all dose cohorts. The Safety Monitoring Committee issued a favorable review of safety data at the maximum dose. In addition, Phio completed a warrant inducement financing in November 2025, securing expected net proceeds of approximately $12.1 million, extending the company's cash runway into the first half of 2027. The company also highlighted recent scientific and investor presentations related to its INTASYL siRNA","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251113:nNDL34cJm9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PHIO","BK4139"],"gpt_icon":0},{"id":"2581884751","title":"Phio Pharmaceuticals Unveils Phase 1b Clinical Results for INTASYL PH-762 in Skin Cancer Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2581884751","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581884751?lang=en_us&edition=fundamental","pubTime":"2025-11-07 23:31","pubTimestamp":1762529473,"startTime":"0","endTime":"0","summary":"Phio Pharmaceuticals Corp. announced that it will present recent clinical data from its ongoing Phase 1b dose escalation clinical trial of INTASYL PH-762, an siRNA-based therapeutic, at the 40th Annual Meeting of the Society for Immunotherapy of Cancer . The trial is evaluating the safety and tolerability of intratumoral injections of PH-762 in patients with cutaneous squamous carcinoma, Merkel cell carcinoma, and melanoma. The poster presentation, titled \"PD-1 Directed Intratumoral Immunotherapy for Cutaneous Carcinomas: A Clinical Study of INTASYL PH-762,\" will be delivered by Mary Spellman, M.D., on November 8, 2025, at the Gaylord National Resort and Convention Center in National Harbor, Maryland. The clinical results will be presented at this upcoming conference.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purpos","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251107:nNDL5RHw6z:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PHIO","BK4139"],"gpt_icon":0},{"id":"2581045839","title":"Phio Pharmaceuticals Exercises Warrants for $13.4 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2581045839","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581045839?lang=en_us&edition=fundamental","pubTime":"2025-11-07 05:38","pubTimestamp":1762465120,"startTime":"0","endTime":"0","summary":"Phio Pharmaceuticals ( ($PHIO) ) just unveiled an update. On November 3, 2025, Phio Pharmaceuticals announced agreements to exercise existing warra...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/phio-pharmaceuticals-exercises-warrants-for-13-4-million?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/phio-pharmaceuticals-exercises-warrants-for-13-4-million?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","PHIO"],"gpt_icon":0},{"id":"2580050249","title":"Phio Pharmaceuticals Shares Rise After Positive Trial Results for PH-762","url":"https://stock-news.laohu8.com/highlight/detail?id=2580050249","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580050249?lang=en_us&edition=fundamental","pubTime":"2025-11-04 02:33","pubTimestamp":1762194780,"startTime":"0","endTime":"0","summary":"Phio Pharmaceuticals shares were higher after the company reported positive pathology results for its Phase 1b Intasyl PH-762 trial.The stock was 32% higher, at $2.72. Shares are up 55% year to date.The biopharmaceutical company reported the pathologic results for three patients with cutaneous squamous cell carcinoma who completed treatment in the fifth and final dose cohort of the on-going Phase 1b dose escalation trial.The company said there was 100% tumor clearance in one of patients, greater than 90% clearance in the second patient, and greater than 50% clearance in the third patient.To date, a total of 18 patients with cutaneous carcinoma have completed treatment across five dose escalating cohorts in the Phase 1b trial. No patients in the study have exhibited clinical progression of disease. Phio may continue to screen and treat additional patients as part of the fifth cohort.The trial is designed to evaluate the safety and tolerability of neoadjuvant use of intratumoral PH-762 i","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4161","LU1988902786.USD","BK4585","LU1064131342.USD","LU0417517546.SGD","PH","BK4580","BK4139","LU0256863811.USD","LU0070302665.USD","LU0211331839.USD","BK4588","LU1989772923.USD","LU0208291251.USD","LU0320765489.SGD","LU0256863902.USD","LU1989772840.SGD","PHIO","LU2264538146.SGD"],"gpt_icon":0},{"id":"2580211022","title":"Why Is Phio Pharmaceuticals Stock Up 75% Today?","url":"https://stock-news.laohu8.com/highlight/detail?id=2580211022","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580211022?lang=en_us&edition=fundamental","pubTime":"2025-11-03 22:24","pubTimestamp":1762179884,"startTime":"0","endTime":"0","summary":"Phio Pharmaceuticals stock soared on Monday alongside new cancer treatment clinical trial results.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/why-is-phio-pharmaceuticals-stock-up-75-today?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/why-is-phio-pharmaceuticals-stock-up-75-today?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PHIO","BK4139"],"gpt_icon":0},{"id":"2580213410","title":"Phio Pharmaceuticals Corp - Safety Committee Issues Favorable Review at Maximum Dose of Intasyl Ph-762- SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2580213410","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580213410?lang=en_us&edition=fundamental","pubTime":"2025-11-03 21:09","pubTimestamp":1762175372,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251103:nFWN3WF11J:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","PHIO"],"gpt_icon":0},{"id":"2579495488","title":"Phio Pharmaceuticals Appoints New Lead Independent Director","url":"https://stock-news.laohu8.com/highlight/detail?id=2579495488","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579495488?lang=en_us&edition=fundamental","pubTime":"2025-10-31 22:57","pubTimestamp":1761922678,"startTime":"0","endTime":"0","summary":"An update from Phio Pharmaceuticals ( ($PHIO) ) is now available. On October 31, 2025, Robert Ferrara resigned from Phio Pharmaceuticals‘ Board of ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/phio-pharmaceuticals-appoints-new-lead-independent-director?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/phio-pharmaceuticals-appoints-new-lead-independent-director?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PHIO","BK4139"],"gpt_icon":0},{"id":"2579349819","title":"Phio Pharmaceuticals Appoints David Deming as Lead Independent Director","url":"https://stock-news.laohu8.com/highlight/detail?id=2579349819","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579349819?lang=en_us&edition=fundamental","pubTime":"2025-10-31 22:15","pubTimestamp":1761920158,"startTime":"0","endTime":"0","summary":"Phio Pharmaceuticals Corp. has announced the appointment of David H. Deming as Lead Independent Director of its Board of Directors. Deming, who joined the board in February 2025, brings more than 30 years of experience in investment banking and asset management, including over 27 years at JP Morgan.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Phio Pharmaceuticals Corp. published the original content used to generate this news brief via Newsfile  on October 31, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251031:nNDL2tfFFG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1366192091.USD","LU2054465674.USD","IE00BKDWB100.SGD","LU1032466523.USD","LU1162221912.USD","LU0323591593.USD","BK4585","IE00BDRTCR15.USD","LU0820561909.HKD","LU2023250504.SGD","IE00B1BXHZ80.USD","LU0689472784.USD","LU1496350171.SGD","LU2237443622.USD","LU1064131342.USD","PHIO","IE00BDCRKT87.USD","LU1116320901.HKD","LU1145028129.USD","LU1496350502.SGD","LU2237443978.SGD","LU0203345920.USD","IE00B1XK9C88.USD","LU0640476718.USD","BK4516","LU0211331839.USD","LU1119994496.HKD","LU1894683348.USD","LU0203347892.USD","IE0034235303.USD","LU2357305700.SGD","LU0215105999.USD","LU0256863811.USD","LU0868494708.USD","LU0265550359.USD","LU2592432038.USD","LU0048584097.USD","LU0238689110.USD","LU2236285917.USD","IE0034235295.USD","LU1116320737.USD","LU1988902786.USD","LU0267386448.USD","IE0034235188.USD","LU0310799852.SGD","LU1280957306.USD","IE00BJTD4V19.USD","LU1261432733.SGD","LU1894683264.USD","LU0976567544.SGD"],"gpt_icon":0},{"id":"2577682273","title":"Phio Pharmaceuticals to Present INTASYL Technology Update at Renmark Financial Virtual Non-Deal Roadshow","url":"https://stock-news.laohu8.com/highlight/detail?id=2577682273","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577682273?lang=en_us&edition=fundamental","pubTime":"2025-10-21 19:45","pubTimestamp":1761047159,"startTime":"0","endTime":"0","summary":"Phio Pharmaceuticals Corp. will participate in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series on October 28, 2025. CEO and Chairman Robert Bitterman will present an update on the company's proprietary INTASYL siRNA technology and share progress from the ongoing clinical trial of lead compound PH-762 for the treatment of skin cancers, including positive interim safety and efficacy results from a Phase 1b trial.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Phio Pharmaceuticals Corp. published the original content used to generate this news brief via Newsfile  on October 21, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251021:nNDL1WscDf:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PHIO"],"gpt_icon":0},{"id":"2569876797","title":"Phio Pharmaceuticals Announces Positive Interim Results in Phase 1b Trial of INTASYL Compound PH-762 for Skin Cancer Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2569876797","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2569876797?lang=en_us&edition=fundamental","pubTime":"2025-09-23 19:45","pubTimestamp":1758627957,"startTime":"0","endTime":"0","summary":"Phio Pharmaceuticals Announces Positive Interim Results in Phase 1b Trial of INTASYL Compound PH-762 for Skin Cancer Treatment. Phio Pharmaceuticals Corp. has announced an update on its ongoing clinical trial involving its lead compound, PH-762, developed using the company's proprietary INTASYL siRNA technology for the treatment of skin cancers. Positive interim safety and efficacy results have been reported from the ongoing Phase 1b dose escalation clinical trial. The details of these findings, along with further information on the INTASYL technology, will be presented by CEO and Chairman Robert Bitterman during a live Virtual Non-Deal Roadshow Series event hosted by Renmark Financial Communications Inc. on September 30, 2025. A replay of the event will be available on Renmark's website.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250923:nNDL1VZk3K:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PHIO"],"gpt_icon":0},{"id":"2567514212","title":"Phio Pharmaceuticals Corp. Conducted Annual Stockholders Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2567514212","media":"Reuters","labels":["executive","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2567514212?lang=en_us&edition=fundamental","pubTime":"2025-09-16 04:01","pubTimestamp":1757966514,"startTime":"0","endTime":"0","summary":"Phio Pharmaceuticals Corp. held its Annual Meeting of Stockholders on September 11, 2025. During the meeting, several key proposals were voted on and approved by the stockholders. The election of six directors was confirmed. The appointment of Grant Thornton, LLP as the company's independent registered public accounting firm for the year ending December 31, 2025, was ratified. An amendment and restatement of the 2020 Long Term Incentive Plan, which increased the number of shares of common stock available for issuance, was approved. Additionally, a non-binding advisory vote approved \"3 years\" as the preferred frequency for future advisory votes on the compensation of the company's named executive officers.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250915:nNDLxMftC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PHIO"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":1,"totalSize":44,"code":"91000000","status":"200"}]}}